Transformative RNA Based Treatments
Targeting the Root Cause of Genetic and Pulmonary Diseases
Our innovative RNA based therapies, based on Antisense Oligonucleotides (ASOs) restore and modify protein functionality, addressing untreatable genetic illnesses and pulmonary diseases.
Transformative RNA-Based Treatments
SpliSense is a company developing transformative RNA-based treatments for unmet needs relating to Cystic Fibrosis (CF) and diverse pulmonary diseases. Our treatment is based on clinically validated Antisense Oligonucleotide (ASO) technology, delivered non-invasively by inhalation to the lungs. We are focused on a variety of innovative therapies, in different development stages from discovery to IND.